Anti-ulcer Effect of Bromocriptine on Indomethacin-induced Gastric Damage in Rats

The anti‐ulcer and gastroprotective effects of bromocriptine were studied in rats. Intraperitoneal administration of bromocriptine (2, 4 and 8 mg kg−1), a dopamine receptor agonist, which also acts on α‐adrenoceptors, prevented indomethacin‐induced gastric ulcer in rats dose‐dependently. This protec...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacy and Pharmacology Communications 2000-09, Vol.6 (9), p.411-413
Main Authors: SAMINI, MORTEZA, MOHAGHEGHI, MASSOUD, HASANZADEH, FARSHAD, DEHPOUR, AHMAD REZA
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti‐ulcer and gastroprotective effects of bromocriptine were studied in rats. Intraperitoneal administration of bromocriptine (2, 4 and 8 mg kg−1), a dopamine receptor agonist, which also acts on α‐adrenoceptors, prevented indomethacin‐induced gastric ulcer in rats dose‐dependently. This protective effect was significantly blocked by the D1‐receptor antagonist, SCH 23390 (1 mg kg−1, i.p.), the D2‐receptor antagonist, sulpride (0.5 mg kg−1, i.p.) and the α2‐receptor antagonist, yohimbine (5 mg kg−1, i.p.), suggesting that the effect of bromocriptine is mediated through dopamine receptors and α‐adrenoceptors. We propose that the anti‐ulcer effect of bromocriptine may be due to a decrease in acid secretion and gastric motility through activation of α2‐adrenoceptors and dopamine D1 receptors.
ISSN:1460-8081
2042-7158
DOI:10.1211/146080800128736286